Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer
NCT00148707
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Metastatic Breast Cancer
Interventions
DRUG:
CT-2103 (Xyotax)
Sponsor
Dana-Farber Cancer Institute
Collaborators
[object Object]
[object Object]